Abstract
Type II diabetes is a heterogeneous disease where environment and genetics are important factors for the expression of the disease. The high cost for treating complications of diabetes is a burden for public health systems and governments worldwide. Type II diabetes has been causing debilitation worldwide for many decades, and a single drug that safely treats the disease has yet to be discovered. Sulfonylureas, biguanides, α-glucosidase, meglitinides, DPP-4 inhibitors and thiazolidinediones are among the classes of oral hypoglycemic drugs available to treat Type II diabetes, but concerns exist regarding safety and efficacy of these drugs. In this article we present the pros and cons of the six classes and discuss some of the latest advances towards the development of new drugs for the treatment of Type II diabetes.
Keywords: Type II Diabetes, oral hypoglycemic agents, insulin-sensitizing drugs, peroxisome proliferators-activated receptors, Dipeptidyl peptidase-4 inhibitors
Current Medicinal Chemistry
Title: Type 2 Diabetes and Oral Antihyperglycemic Drugs
Volume: 15 Issue: 1
Author(s): Mitchell A. Avery, Cassia S. Mizuno, Amar G. Chittiboyina, Theodore W. Kurtz and Harrihar A. Pershadsingh
Affiliation:
Keywords: Type II Diabetes, oral hypoglycemic agents, insulin-sensitizing drugs, peroxisome proliferators-activated receptors, Dipeptidyl peptidase-4 inhibitors
Abstract: Type II diabetes is a heterogeneous disease where environment and genetics are important factors for the expression of the disease. The high cost for treating complications of diabetes is a burden for public health systems and governments worldwide. Type II diabetes has been causing debilitation worldwide for many decades, and a single drug that safely treats the disease has yet to be discovered. Sulfonylureas, biguanides, α-glucosidase, meglitinides, DPP-4 inhibitors and thiazolidinediones are among the classes of oral hypoglycemic drugs available to treat Type II diabetes, but concerns exist regarding safety and efficacy of these drugs. In this article we present the pros and cons of the six classes and discuss some of the latest advances towards the development of new drugs for the treatment of Type II diabetes.
Export Options
About this article
Cite this article as:
Avery A. Mitchell, Mizuno S. Cassia, Chittiboyina G. Amar, Kurtz W. Theodore and Pershadsingh A. Harrihar, Type 2 Diabetes and Oral Antihyperglycemic Drugs, Current Medicinal Chemistry 2008; 15 (1) . https://dx.doi.org/10.2174/092986708783330656
DOI https://dx.doi.org/10.2174/092986708783330656 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Involvement of IL-1R/TLR Signalling in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis
Current Molecular Medicine Cannabinoid Hyperemesis Syndrome
Current Drug Abuse Reviews Identification of AHSA1 as a Potential Therapeutic Target for Breast Cancer: Bioinformatics Analysis and <i>in vitro</i> Studies
Current Cancer Drug Targets Pathogenesis and Subtype of Intracerebral Hemorrhage (ICH) and ICH Score Determines Prognosis
Current Neurovascular Research Editorial [Hot Topic:Applications of Angiotensin Converting Enzyme Inhibitors and of Angiotensin II Receptor Blockers in Pharmacology and Therapy: An Update (Executive Editor: Agostino Molteni)]
Current Pharmaceutical Design Silk Fibroin Based Drug Delivery Applications: Promises and Challenges
Current Drug Targets Novel Risk Factors Related to Stable Angina
Current Pharmaceutical Design Prescription Patterns of Antidiabetic Treatment in the Elderly. Results from Southern Italy
Current Diabetes Reviews Flaxseed for Health and Disease: Review of Clinical Trials
Combinatorial Chemistry & High Throughput Screening Prognostic Implications of microRNA-155, -133a, -21 and -205 in Breast Cancer Patients’ Plasma
MicroRNA C75, a Fatty Acid Synthase (FAS) Inhibitor
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Measurement and Mapping of Retinal Leakage and Retinal Thickness - Surrogate Outcomes for the Initial Stages of Diabetic Retinopathy
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Tumor-Associated Macrophages as Potential Targets for Anti-Cancer Activity of Marine Invertebrate-Derived Compounds
Current Pharmaceutical Design Chemotherapeutic Properties of n-3 Polyunsaturated Fatty Acids - Old Concepts and New Insights
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Melanin Concentrating Hormone Receptor Antagonists as Antiobesity Agents: From M2 to MCHR-1
Current Topics in Medicinal Chemistry Subject Index To Volume 6
Cardiovascular & Hematological Disorders-Drug Targets Interaction between Thienopyridines and Proton Pump Inhibitors
Cardiovascular & Hematological Disorders-Drug Targets Aspergillus Biotechnology: An Overview on the Production of Hydrolases and Secondary Metabolites
Current Biotechnology Treatment Strategies for Hypercholesterolemia
Current Pediatric Reviews Glycogen Synthase Kinase-β3 in Ischemic Neuronal Death
Current Neurovascular Research